The KRAS-G12C inhibitor: activity and resistance

Research output: Contribution to journalEditorialpeer-review

21 Scopus citations


Although it has long been deemed “undruggable”, with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS have recently made promising improvements. In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS-G12C mutations. Unfortunately, the vast majority of patients do not respond to KRAS-G12C inhibitor therapy, mainly due to intrinsic or acquired resistance caused by cellular, molecular, and genetic mechanisms. Improving the understanding of drug response in the tumor microenvironment may continue to promote the design, testing, and clinical application of KRAS-G12C inhibitors.

Original languageEnglish (US)
JournalCancer Gene Therapy
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research


Dive into the research topics of 'The KRAS-G12C inhibitor: activity and resistance'. Together they form a unique fingerprint.

Cite this